SEP 07, 2016 12:00 PM PDT
Community Acquired Bacterial Pneumonia- a 2016 perspective.
Presented at the Microbiology & Immunology Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
2 2 134

Speakers:
  • Consultant Medical Microbiologist
    Biography
      Glenn Tillotson has 30+ years pharmaceutical experience in early pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs. Dr Tillotson has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin and most recently solithromycin. Glenn has held several key committee positions at the American College of Chest Physicians, he is on the Scientific Steering Committee for the GTCBio the Annual Summit on Anti-infective Partnering. Currently Dr Tillotson has published >150 peer-reviewed manuscripts, presented >270 scientific posters and is on several journal Editorial Advisory Boards including the Lancet Infectious Disease, eBioMedicine Expert Reviews in Anti-Infective Therapy and F1000.

    Abstract:

    Community acquired pneumonia affects over 5 million Americans and 6 million Europeans annually. Typically 5-10% will be admitted to hospital. It is a condition that more often affects the elderly with a commensurately higher mortality rate, which can be as high as 25%. Indeed over 50,000 deaths occur in the USA each year due to this infection. Diagnosis of pneumonia is almost exclusively clinical in terms of signs and symptoms although a positive chest X ray is vital.

    Approximately half of all pneumonia infections are caused by bacteria, the remainder are viral in origin. Streptococcus pneumoniae accounts for the majority of the bacterial cases. As with many other bacterial species the pneumococcus is becoming resistant to many of the commonly used antibiotics. As a result the US FDA has re-assigned the infection to be called Community Acquired Bacterial Pneumonia (CABP).

    Learned guidelines recommend either a macrolide or a doxycycline as the first choices for the low risk patient or a respiratory fluoroquinolone for those at higher risk or who have failed an initial course. Resistance to both first line agents is increasing in the USA   leading to a growing list of adverse consequences such as emergency room visits, hospitalization or re-admission to hospital. This presentation will review the current knowledge of the disease and the challenges of managing these patients.

    Learning Objective 1 : to appreciate the escalating burden of CABP in the USA

    Learning Objective 2 : to understand the impact antibiotic resistance can have in CABP

    Learning Objective 3 : to understand the current challenges in managing CABP
     


    Show Resources
    Loading Comments...